Grifols, S.A. (NASDAQ:GRFS - Get Free Report) shares crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $8.67 and traded as high as $10.06. Grifols shares last traded at $9.83, with a volume of 727,663 shares trading hands.
Analyst Ratings Changes
A number of research analysts have recently commented on the stock. JPMorgan Chase & Co. upped their price objective on shares of Grifols from $7.60 to $10.30 and gave the company a "neutral" rating in a research report on Tuesday, June 17th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Grifols in a research report on Tuesday, August 5th. Zacks Research raised shares of Grifols to a "hold" rating in a research report on Friday, August 8th. Finally, Wall Street Zen raised shares of Grifols from a "buy" rating to a "strong-buy" rating in a research report on Monday, July 7th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $10.30.
Read Our Latest Analysis on Grifols
Grifols Price Performance
The company has a debt-to-equity ratio of 1.20, a current ratio of 2.64 and a quick ratio of 0.95. The company's 50 day moving average price is $10.13 and its 200 day moving average price is $8.70. The firm has a market capitalization of $6.70 billion, a P/E ratio of 8.32, a PEG ratio of 0.33 and a beta of 0.64.
Grifols Dividend Announcement
The business also recently declared a special dividend, which was paid on Wednesday, August 20th. Stockholders of record on Tuesday, August 12th were paid a dividend of $0.1404 per share. The ex-dividend date of this dividend was Tuesday, August 12th. Grifols's dividend payout ratio is 11.97%.
Institutional Trading of Grifols
Hedge funds have recently modified their holdings of the stock. Versant Capital Management Inc bought a new position in Grifols in the first quarter valued at approximately $28,000. EverSource Wealth Advisors LLC boosted its stake in Grifols by 127.4% in the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company's stock valued at $74,000 after acquiring an additional 4,604 shares during the last quarter. Ballentine Partners LLC bought a new position in Grifols in the first quarter valued at approximately $77,000. R Squared Ltd bought a new position in Grifols in the second quarter valued at approximately $95,000. Finally, Ameriprise Financial Inc. acquired a new stake in Grifols in the second quarter worth $95,000.
Grifols Company Profile
(
Get Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Read More
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
